

Supporting Information for

Inherent chirality through a simple dialkylation of 2,14-dithiacalix[4]arene

Daniel Kortus,[†]Ondřej Kunderát,[†] Martin Tlustý,[†] Jan Čejka,[†] Hana Dvořáková[‡] and Pavel Lhoták^{†*}

[†]Department of Organic Chemistry, University of Chemistry and Technology, Prague (UCTP),

Technická 5, 166 28 Prague 6, Czech Republic

[‡]Solid State Department, UCTP, 166 28 Prague 6, Czech Republic.

^{*}Laboratory of NMR spectroscopy, UCTP, 166 28 Prague 6, Czech Republic.

Table of contents

1. Spectral characterisation	2
2. Crystallographic structures	25
3. HPLC Measurements	30

1. SPECTRAL CHARACTERISATION




Figure 1. ¹H NMR of compound 4 (CD₂Cl₂, 600 MHz).




Figure 2. ¹³C NMR of compound 4 (CD₂Cl₂, 151 MHz).




Figure 3. HMBC NMR of compound **4** (CD_2Cl_2).




Figure 4. HMQC NMR of compound **4** (CD_2Cl_2).




Figure 5. COSY NMR of compound **4** (CD_2Cl_2).

117_Kortus_ESIpos_DK69_F1_1 4/2/2019 7:37:04 AM
 MeOH
 117_Kortus_ESIpos_DK69_F1_1 #53-55 RT: 0.75-0.78 AV: 3 NL: 3.91E7
 T: FTMS + c ESI Full ms [200.00-2000.00]




Figure 6. HRMS of compound **4** (ESI^+).




Figure 7. IR of compound 4 (KBr).




Figure 8. ^1H NMR of compound 5 (CDCl_3 , 600 MHz).




Figure 9. ^{13}C NMR of compound **5** (CDCl_3 , 151 MHz).




Figure 10. HMBC NMR of compound **5** (CDCl_3).




Figure 11. HMQC NMR of compound **5** (CDCl_3).




Figure 12. COSY NMR of compound **5**.

90_Kortus_ESIpos_DK70_F2_1
MetOH
6/4/2020 10:03:19 AM
90_Kortus_ESIpos_DK70_F2_1 #15-29 RT: 0.21-0.41 AV: 15 NL: 1.06E7
T: FTMS + c ESI Full ms [200.00-2000.00]




Figure 13. HRMS of compound 5 (ESI⁺).




Figure 14. IR of compound 5 (KBr).




Figure 15. ^1H NMR of compound **6** (CD_2Cl_2 , 600 MHz).




Figure 16. ^{13}C NMR of compound **6** (CD_2Cl_2 , 151 MHz).




Figure 17. HMBC NMR of compound **6** (CD_2Cl_2).




Figure 18. HMQC NMR of compound **6** (CD_2Cl_2).



Figure 19. COSY NMR of compound **6** (CD_2Cl_2).

149_Kortus_ESIpos_DK72_F2_1
MeOH

4/24/2019 8:04:39 AM

149_Kortus_ESIpos_DK72_F2_1 #46-49 RT: 0.66-0.70 AV: 4 NL: 6.32E7
T: FTMS + c ESI Full ms [200.00-2000.00]




Figure 20. HRMS of compound **6** (ESI^+).




Figure 21. IR of compound 6 (KBr).




Figure 22. ^1H NMR of compound 8 (CDCl_3 , 600 MHz).




Figure 23. ^{13}C NMR of compound **8** (CDCl_3 , 151 MHz).




Figure 24. HMBC NMR of compound **8** (CDCl_3).




Figure 25. HMQC NMR of compound **8** (CDCl_3).



Figure 26. COSY NMR of compound **8** (CDCl_3).




Figure 27. HRMS of compound 8 (ESI⁺).




Figure 28. IR of compound 8 (KBr).




Figure 29. ^1H NMR of compound **9** (CDCl_3 , 600 MHz).




Figure 30. ^{13}C NMR of compound **9** (CDCl_3 , 151 MHz).




Figure 31. HMBC NMR of compound **9** (CDCl₃).




Figure 32. HMQC NMR of compound **9** (CDCl₃).




Figure 33. COSY NMR of compound **9** (CDCl_3).

14_Kortus_ESIpos_DK151_1 4/3/2020 3:13:14 PM
 MetOH
 14_Kortus_ESIpos_DK151_1 #27-32 RT: 0.38-0.46 AV: 6 NL: 1.88E7
 T: FTMS + c ESI Full ms [250.00-2000.00]




Figure 34. HRMS of compound **9** (ESI^+).




Figure 37. ^{13}C NMR of compound **10** (CDCl_3 , 151 MHz).




Figure 38. HMBC NMR of compound **10** (CDCl_3).




Figure 39. HMBC NMR of compound **10** (CDCl_3).




Figure 40. COSY NMR of compound **10** (CDCl_3).




Figure 41. HRMS of compound 10 (ESI⁺).




Figure 42. IR of compound 10 (KBr).




Fig. 44. Comparison of partial ^1H NMR spectra (aromatic region) of **8**, **9** and **10** (298 K, CDCl_3 , 600 MHz).

2. CRYSTALLOGRAPHIC STRUCTURES




Figure 45. Crystallographic structures of two enantiomers of compound 4.




Figure 46. Crystallographic structure of compound **4** - three symmetrically independent molecules in the unit cell, two of them containing solvent molecule (DCM).




Figure 47. Crystallographic structure of compound 5.




Figure 48. Crystallographic structures of two diastereomers of compound **8**.




Figure 49. Crystallographic structures of two diastereomers of compound **10**.

3. HPLC MEASUREMENTS

Compounds **4**, **8** and **9** were subjected to HPLC on a chiral column Chiralpak IA (250 × 4.6 mm ID, 10 μm) using heptane:CH₂Cl₂ = 90:10 or 95:5 v/v as a mobile phase. Flow rate was 0.7 mL min⁻¹, column temperature 298 K and detection wavelength 254 nm. These conditions have led to a base-line separation of two peaks.




Figure 50. HPLC measurement of compound **4**, mobile phase: heptane:CH₂Cl₂ = 90:10, retention times: 8.55 and 10.22 min.




Figure 51. HPLC measurement of compound **8**, mobile phase: heptane:CH₂Cl₂ = 95:5, retention times: 5.42 and 5.76 min.




Figure 52. HPLC measurement of compound **9**, mobile phase: heptane:CH₂Cl₂ = 95:5, retention times: 6.20 and 10.22 min.